Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 25, Pages 3091-3099
Publisher
American Society of Clinical Oncology (ASCO)
Online
2013-08-06
DOI
10.1200/jco.2012.47.8313
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
- (2013) Heidi D. Nelson ANNALS OF INTERNAL MEDICINE
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
- (2012) N. Mavaddat et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
- (2011) K Metcalfe et al. BRITISH JOURNAL OF CANCER
- Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
- (2011) Antonis C Antoniou et al. HUMAN MOLECULAR GENETICS
- Medication to prevent breast cancer - too much to swallow?
- (2011) Sandra L Harvey et al. MEDICAL JOURNAL OF AUSTRALIA
- Report of Endometrial Cancer in Australian BRCA1 and BRCA2 Mutation-Positive Families
- (2011) David L. Duffy et al. Twin Research and Human Genetics
- Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
- (2010) Kerryn W. Reding et al. BREAST CANCER RESEARCH AND TREATMENT
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
- (2010) Susan M. Domchek JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation inBRCA1orBRCA2
- (2010) Kathleen E. Malone et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of mammary stem cell function by steroid hormone signalling
- (2010) Marie-Liesse Asselin-Labat et al. NATURE
- Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
- (2009) Belinda E. Kiely et al. BREAST CANCER RESEARCH AND TREATMENT
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
- (2009) Kala Visvanathan et al. JOURNAL OF CLINICAL ONCOLOGY
- Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
- (2009) Monika K. Graeser et al. JOURNAL OF CLINICAL ONCOLOGY
- Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
- (2009) A. W. Kurian et al. JNCI-Journal of the National Cancer Institute
- Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
- (2009) T. R. Rebbeck et al. JNCI-Journal of the National Cancer Institute
- Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers
- (2008) Maria M Litwiniuk et al. BMC CANCER
- International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers
- (2008) Kelly A. Metcalfe et al. INTERNATIONAL JOURNAL OF CANCER
- Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
- (2008) Nienke M. van der Velde et al. INTERNATIONAL JOURNAL OF CANCER
- Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group
- (2008) Kelly A. Metcalfe et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started